Cargando…

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement

Detalles Bibliográficos
Autores principales:	Rigaud, Charlotte, Abbou, Samuel, Ducasso, Stéphane, Simonin, Mathieu, Le Mouel, Lou, Pereira, Victor, Gourdon, Stéphanie, Lambilliotte, Anne, Geoerger, Birgit, Minard-Colin, Véronique, Brugières, Laurence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425319/ https://www.ncbi.nlm.nih.gov/pubmed/35586965 http://dx.doi.org/10.3324/haematol.2021.280081

Ejemplares similares

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
por: Verran, Julian, et al.
Publicado: (2022)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
por: Harrer, Dennis Christoph, et al.
Publicado: (2020)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Future Perspective for ALK-Positive Anaplastic Large Cell Lymphoma with Initial Central Nervous System (CNS) Involvement: Could Next-Generation ALK Inhibitors Replace Brain Radiotherapy for the Prevention of Further CNS Relapse?
por: Tanaka, Makito, et al.
Publicado: (2023)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Pathobiology of ALK-negative anaplastic large cell lymphoma
por: Pileri, Stefano A., et al.
Publicado: (2011)

ALK-positive anaplastic large cell lymphoma in adults
por: Gromowsky, Matthew J, et al.
Publicado: (2023)

Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects
por: Petrazzuolo, Adriana, et al.
Publicado: (2021)

NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma
por: Haque, Moinul, et al.
Publicado: (2019)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
por: Singh, Vijay Kumar, et al.
Publicado: (2019)

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2022)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
por: Satou, Akira, et al.
Publicado: (2020)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Primary Central Nervous System ALK Positive Anaplastic Large Cell Lymphoma with Predominantly Leptomeningeal Involvement in an Adult
por: Park, Jae Sung, et al.
Publicado: (2013)

Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement
por: Magaki, Shino, et al.
Publicado: (2021)

Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease
por: Lawrence, Kasey, et al.
Publicado: (2015)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

Systematic Review and Network Meta-Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Treatment-Naïve ALK-Positive Lung Cancer
por: Chuang, Cheng-Hao, et al.
Publicado: (2021)

An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
por: Turner, Suzanne D.
Publicado: (2017)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Status of the anaplastic lymphoma kinase (ALK) gene in inflammatory breast carcinoma
por: Krishnamurthy, Savitri, et al.
Publicado: (2013)

ALK-positive anaplastic large cell lymphoma that presented as pleural effusion
por: Kim, Do Hwan, et al.
Publicado: (2022)

ALK-Positive Anaplastic Large Cell Lymphoma Associated With Hemophagocytic Lymphohistiocytosis
por: Chao, Shing, et al.
Publicado: (2023)

Central nervous system involvement of systemic ALK-positive histiocytosis with KIF5B-ALK fusion
por: Aoki, Yuzuna, et al.
Publicado: (2022)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report
por: Dong, Xiaoqin, et al.
Publicado: (2016)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma
por: Subbiah, V., et al.
Publicado: (2021)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
por: van der Krogt, Jo-Anne, et al.
Publicado: (2017)

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
por: Daugrois, Camille, et al.
Publicado: (2021)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_9lbfdrsi2l06fr1k5c8u7ckdfs